(NASDAQ: INSM) Insmed's forecast annual revenue growth rate of 74.04% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 87.9%, and while it is forecast to beat the US market's average forecast revenue growth rate of 11.62%.
Insmed's revenue in 2025 is $381,030,000.On average, 7 Wall Street analysts forecast INSM's revenue for 2025 to be $85,527,338,351, with the lowest INSM revenue forecast at $81,707,520,858, and the highest INSM revenue forecast at $88,692,548,555. On average, 7 Wall Street analysts forecast INSM's revenue for 2026 to be $188,540,924,005, with the lowest INSM revenue forecast at $170,609,529,174, and the highest INSM revenue forecast at $213,290,143,001.
In 2027, INSM is forecast to generate $380,732,822,721 in revenue, with the lowest revenue forecast at $315,173,192,359 and the highest revenue forecast at $455,711,585,346.